Psychiatric aspects in Parkinsonism treated with L-dopa.
Psychiatric aspects of patients with Parkinsonism treated with L-dopa are described. These include acute psychosis in patients with or without previous psychiatric illness and worsening or improvement of pre-existing psychiatric conditions. Therapeutic management is discussed The relevance of these studies to the understanding of the psychiatric aspects of Parkinsonism in general is discussed.
D000339:Affect; D000368:Aged; D000928:Antidepressive Agents / Q000627:therapeutic use; D001007:Anxiety; D001143:Arousal; D001463:Barbiturates / Q000627:therapeutic use; D003072:Cognition Disorders / Q000139:chemically induced; D003863:Depression / Q000139:chemically induced; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D004336:Drug Antagonism; D004347:Drug Interactions; D005260:Female; D006212:Hallucinations / Q000139:chemically induced; D006801:Humans; D008297:Male; D008875:Middle Aged; D009497:Neurotic Disorders / Q000139:chemically induced*; D010300:Parkinson Disease / Q000150:complications / Q000188:drug therapy*; D011605:Psychoses, Substance-Induced / Q000209:etiology*; D011613:Psychotherapy; D012890:Sleep; D014149:Tranquilizing Agents / Q000627:therapeutic use; D014785:Vision, Ocular
D000928:Antidepressive Agents; D001463:Barbiturates; D014149:Tranquilizing Agents; D004295:Dihydroxyphenylalanine